Is Immunodiagnostic Systems Holdings PLC's (LON:IDH) 1.4% ROE Worse Than Average?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of learning-by-doing, we'll look at ROE to gain a better understanding of Immunodiagnostic Systems Holdings PLC (LON:IDH).

Our data shows Immunodiagnostic Systems Holdings has a return on equity of 1.4% for the last year. One way to conceptualize this, is that for each £1 of shareholders' equity it has, the company made £0.014 in profit.

Check out our latest analysis for Immunodiagnostic Systems Holdings

How Do You Calculate Return On Equity?

The formula for return on equity is:

Return on Equity = Net Profit ÷ Shareholders' Equity

Or for Immunodiagnostic Systems Holdings:

1.4% = UK£796k ÷ UK£55m (Based on the trailing twelve months to March 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. You can calculate shareholders' equity by subtracting the company's total liabilities from its total assets.

What Does ROE Signify?

ROE measures a company's profitability against the profit it retains, and any outside investments. The 'return' is the profit over the last twelve months. That means that the higher the ROE, the more profitable the company is. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

Does Immunodiagnostic Systems Holdings Have A Good Return On Equity?

By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. As shown in the graphic below, Immunodiagnostic Systems Holdings has a lower ROE than the average (13%) in the Medical Equipment industry classification.

AIM:IDH Past Revenue and Net Income, June 24th 2019
AIM:IDH Past Revenue and Net Income, June 24th 2019

That certainly isn't ideal. We prefer it when the ROE of a company is above the industry average, but it's not the be-all and end-all if it is lower. Nonetheless, it might be wise to check if insiders have been selling.

How Does Debt Impact ROE?

Most companies need money -- from somewhere -- to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first and second cases, the ROE will reflect this use of cash for investment in the business. In the latter case, the use of debt will improve the returns, but will not change the equity. Thus the use of debt can improve ROE, albeit along with extra risk in the case of stormy weather, metaphorically speaking.